Evaluation of platinum contamination of a hazardous drug preparation area in a hospital pharmacy;Évaluation de la contamination par le platine d'une unité centralisée de préparation des médicaments cytotoxiques

Bulletin du Cancer

Volumn 89, Issue 11, 2002, Pages 949-955

  Leboucher, Gilles ^a   Serratrice, François ^a   Bertholle, Valérie ^a   Thore, Laurence ^a   Bost, Muriel ^b  

^a CROIX ROUSSE HOSPITAL   (France)

^b EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

Centralized preparation unit; Contamination; Hazardous drugs; Platinum; Protection

Indexed keywords

CISPLATIN; NEOPRENE; PLATINUM; ANTINEOPLASTIC AGENT;

ARTICLE; ATOMIC ABSORPTION SPECTROMETRY; DRUG SAFETY; ENVIRONMENTAL EXPOSURE; GOOD MANUFACTURING PRACTICE; HOSPITAL PHARMACY; OCCUPATIONAL SAFETY; PERSONNEL; PRACTICE GUIDELINE; CHEMISTRY; EQUIPMENT; HUMAN; OCCUPATIONAL EXPOSURE; WORKPLACE;

ANTINEOPLASTIC AGENTS; CHEMISTRY, PHARMACEUTICAL; EQUIPMENT CONTAMINATION; HUMANS; OCCUPATIONAL EXPOSURE; PHARMACY SERVICE, HOSPITAL; PLATINUM; WORKPLACE;

EID: 0036826946     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. e Édition. Dossier du CNHIM 2001; XXII; 424 p.
2. Sessink P, Bos R. Drugs hazardous to healthcare workers: Evaluation of methods for monitoring occupational exposure to cytostatic drugs. Drug Saf 1999; 20:47-59.
3. Falck K, Grohn P, Sorsa M, Valnio H, Heinoven E, Holsti L. Mutagenicity in urine of nurses handling cytostatic drugs. Lancet 1979; 1: 1250-1.
4. Anderson R, Puckett W, Dana W, Nguyen T, Theiss J, Matney T. Risk of handling injectable antineoplastic agents. Am J Hosp Pharm 1982; 39:1881-7.
5. Cloak M, Connor T, Stevens K, Theiss J, Alt J, Matney T, et al. Occupational exposure of nursing personnel to antineoplastic agents. Oncol Nuts Forum 1985; 12:33-9.
6. Baker E, Connor T. Monitoring occupational exposure to cancer chemotherapy drugs. Am J Health Syst Pharm 1996; 53:2713-23.
7. Occupational Safety and Health Administration. Controlling occupational exposure to hazardous drugs. Am J Health Syst Pharm 1996; 53: 1669-85.
8. Power L, Anderson R, Cortopassi R, Gera J, Lewis R. Update on safe handling of hazardous drugs: The advice of experts. Am J Hosp Pharm 1990; 47:1050-60.
9. Rasmussen H. Handling cytotoxics in Scandinavia. EHP 1998; 4 (suppl. 1): S20-S21.
10. Swart EL. Safe handling of cytotoxic drugs: Experiences with the implementation of new guidelines in the Netherlands. EHP 1998; 4 (suppl. 1): S17-S19.
11. Vigneron J, Cholvy-Laurelli F, May I, Perrin A, Hoffman MA, Hoffman M. La Préparation Hospitalière des Thérapeutiques Anticancéreuses. Lyon: Laboratoire Aguettant, 1993; 246 p.
12. Bochaton C, Leboucher G, Brandon MT, Charpiat B. Conception et mise en place d'une unité de préparation centralisée des medicaments injectables en atmosphere controlée. Pharm Hosp Fra 1996; 117:107-16.
13. Connor T, Anderson R, Sessink P, Broadfield L, Power L. Surface contamination with antineoplastic agents in six cancer treatment centers in Canada and the United States. Am J Health Syst Pharm 1999; 56: 1427-32.
14. Favier B, Rull F, Bertucat H, Pivot C, Leboucher G, Charlety D, et al. Évaluation de la contamination de l'environnement matériel et humain par le 5-fluoro-uracile lors de la manipulation en unités de reconstitution des chimiothérapies. J Pharm Clin 2001; 20:157-62.
15. Apostoli P, Clonfero E, Cottica D, Bergamashi A, Moccaldi R, Draicchio F, et al. Criteria and methods for study of occupational exposure to antineoplastic drugs. Med Lav 1996; 7:230-54.
16. Forni A, Alessio L, Cortona G, Erba P, Feltrin G, Pesatori A. The health surveillance of personnel who handle antineoplastic agents. Med Lav 1996; 87:265-7.
17. Larson RR, Khazaeli MB, Kenneth Dillon H. Monitoring method for surface contamination caused by selected antineoplastic agents. Am J Health Syst Pharm 2002; 59:270-7.
18. Schmaus G, Schierl R, Funck S. Monitoring surface contamination by antineoplastic drugs using gas chromatography-mass spectrometry and voltametry. Am J Health Syst Pharm 2002; 59:956-61.
19. Sessink P, Anzion R, Van den Broek P, Bos R. Detection of contamination with antineoplastic agents in a hospital pharmacy department. Pharm Weekbl Sci 1992; 4:16-22.
20. Harrison BR, Godefroid RJ, Kavanaugh EA. Quality-assurance testing of staff pharmacists handling cytotoxic agents. Am J Health Syst Pharm 1996; 53:402-7.
21. Delporte J, Chenoix P, Hubert P. Chemical contamination of the primary packaging of 5-fluorouracil rtu solutions commercially available on the belgian market. EHP 1999; 5:119-21.
22. Serratrice F. Manipulation des Medicaments Anticancéreux dans une Unité de Reconstitution Centralisée: Évaluation des Procédures et du Risque d'Exposition des Personnels aux Cytotoxiques. Th D Pharm Lyon: 2000, no 28.
23. Martindale editorial staff. Martindale: The Complete Drug Reference. 32nd Edition. London: Pharmaceutical Press, 1999; 513.
24. Connor T. Permeability of nitrile rubber, latex, polyurethane and neoprene gloves to 18 antineoplastic drugs. Am J Health Syst Pharm 1999; 56:2450-3.